Tianda Pharmaceuticals Ltd. (HK:0455) has released an update.
Tianda Pharmaceuticals Ltd. has announced its wholly-owned subsidiary received approval from China’s National Medical Products Administration for an ibuprofen suspension for children. The new product is expected to enhance the company’s pediatric portfolio and market presence. This development is part of Tianda’s strategic growth, with seven new products anticipated to launch in the next two years.
For further insights into HK:0455 stock, check out TipRanks’ Stock Analysis page.
